Involvement of epithelial–mesenchymal transition in liver fibrosis

Kangkang Yu, Qian Li, Guangfeng Shi, Ning Li

Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, Department of General Surgery, Qingdao Municipal Hospital, Qingdao, People’s Republic of China

INTRODUCTION

The epithelial–mesenchymal transition (EMT) is a process by which epithelial cells lose their cell polarity and cell–cell adhesion, and acquire migratory and invasive properties to become mesenchymal cells.[1,2] EMT was first observed in embryogenesis and was critical for the development of tissues and organs.[3,4] EMT is not irreversible; together with its reverse process mesenchymal–epithelial transition (MET), EMT plays crucial roles in cancer progression,[5,6] wound healing,[2,7] and organ fibrosis.[1,2,8,9] Liver fibrosis is a protective response to chronic liver injury from diverse etiologies.[10–12] The feature of liver fibrosis is the excessive accumulation of extracellular matrix (ECM) produced by myofibroblasts.[13] Activated hepatic stellate cells (HSCs) are believed to be the primary source of myofibroblasts.[14] Advanced liver fibrosis results in cirrhosis, portal hypertension, even liver failure, and other life-threatening complications and only liver transplantation will rescue the patients.[10,15] Recently, EMT was implicated in liver fibrosis.[16–18] As research continues, however, the notion becomes controversial.[19,20]
These transformed cells usually share common mesenchymal phenotypes and have the potential to undergo a reverse process, namely MET, to generate epithelial cells. Type 2 EMT was implicated in wound healing, tissue regeneration, and organ fibrosis. This kind of EMT usually occurs following tissue injuries such as inflammation, and forms fibroblasts to repair injured tissue. Once inflammation receded, the transition ceased. However, in fibrotic organs, the EMT continuously responded to inflammation, and result in organ destruction ultimately. The third proposed subtype of EMT is Type 3 EMT, which occurs in cancer cells that have previously undergone genetic and epigenetic alterations. Through this transition, neoplastic cells may invade and metastasize via the circulation and finally lead to cancer progression and metastasis.

**MAIN LIVER CELL TYPES INVOLVED IN EMT**

**Hepatocyte and EMT**

In fibrotic liver, the identified origin of collagen-producing cells includes activated HSCs, portal fibroblasts, and bone marrow-derived myofibroblasts. However, evidence from research suggested that hepatocytes could also acquire a fibroblastic phenotype through EMT in liver fibrosis. Zeisberg et al. found that upon stimulation with transforming growth factor β-1 (TGF-β1), adult mouse hepatocytes underwent changes phenotypically as well as functionally. In addition, using lineage-tracing technique, they observed that hepatocytes-derived cells demonstrated with fibroblast-like morphology and with expression of fibroblast-specific protein 1 (FSP-1), and this report provides the first *in vivo* evidence for hepatocyte EMT. Similarly, other research also revealed that hepatocytes actively participate in fibrogenesis through TGF-β-dependent EMT. Dooley et al. confirmed a coexpression of collagen and transferrin in liver samples from patients with HBV infection, indicating the possible occurrence of EMT. They also found that specific inhibition of TGF-β signaling in hepatocyte-derived cells can attenuate fibrogenic response. Lee et al. demonstrated that apamin can inhibit TGF-β1-induced E-cadherin loss and vimentin increase *in vitro*, and prevent CCL4-induced liver fibrosis *in vivo*. This suggests that through suppressed TGF-β1-induced hepatocyte EMT, apamin can inhibit hepatic fibrogenesis. Kong et al. found that cobalt chloride (CoCl₂) can upregulate mesenchymal markers, including vimentin, N-cadherin, and α-smooth muscle actin (α-SMA) and thus induce a mesenchymal cell phenotype in hepatocytes. They further confirmed that curcumin, a natural antifibrotic compound, can repress this process by decreasing TGF-β receptor expression and inhibiting Smad2/3 expression and phosphorylation. Other studies suggest that geniposide and celecoxib can inhibit hepatocytes EMT in liver fibrosis as well. These findings provided potential strategies to prevent liver fibrosis by targeting hepatocytes EMT. However, a recent study reported that mouse hepatocytes do not undergo EMT in liver fibrosis. Using transgenic mice, Taura et al. found that hepatocytes do assume a TGF-β-induced fibroblast-like morphology, but failed to express mesenchymal markers including FSP-1, α-SMA, and vimentin. They also confirmed that hepatocytes are not the origin of type I collagen-producing cells in liver fibrosis. These results were quite different from the previous work performed by Zeisberg and his colleagues. Taura et al. hold that β-Gal staining in Zeisberg study may yield false-positive results due to technical limitations. Although Taura and colleagues’ work effectively challenges the existence of hepatocyte EMT, lineage tracing technique has its own pitfalls and it is still too early to exclude EMT in liver fibrosis completely.

**Cholangiocyte and EMT**

Cholangiocyte, another cell type which has been proposed, contributes to liver fibrosis through EMT. Omenetti et al. provided direct evidence of the contribution of cholangiocyte EMT to liver fibrosis. In their study, the investigators found that cholangiocytes isolated from rats with biliary fibrosis induced by bile duct ligation (BDL) expressed high level of FSP-1 and low level of aquaporin-1 and cytoketarin 7/9 (Krt7/9). In addition, they demonstrated that an immature cholangiocyte line cocultured with myofibroblastic HSCs (MF-HSC), or treated with activated HSC conditioned medium, was induced to undergo complete EMT by silencing epithelial gene expression, inducing mesenchymal gene expression and acquiring a migratory phenotype. Moreover, they confirmed that inhibiting Hedgehog (Hh) signaling pathway can block EMT in the cholangiocytes under MF-HSC conditioned medium treatment. Several other studies found cholangiocytes from rats with biliary fibrosis or human tissues coexpressed epithelial and mesenchymal markers. In biliary atresia, evidence also support that biliary epithelial cells may directly contribute to fibrogenesis via EMT. Diaz et al. provided histological evidence, suggesting that EMT occurs in biliary atresia. In
consistence with this, Xiao et al. showed that Krt7 and α-SMA colocalized to the intrahepatic biliary epithelial cells in patients with biliary atresia. Besides, they demonstrated that EMT in primary human intrahepatic biliary epithelial cells was induced by TGF-β and confirmed that the process can be inhibited significantly by miR-200b. Seemingly, there is solid evidence that cholangiocytes can contribute to fibrosis via EMT. However, the authenticity of cholangiocyte EMT was seriously challenged recently. Using cell fate tracing technique, Scholten et al. revealed that no EMT of cholangiocytes was identified by genetic labeling that contributes to liver fibrosis in mice. Actually, the investigators detected no coexpression of myofibroblast marker and cholangiocyte marker in both biliary and panlobular fibrosis. In addition, they also showed that no epithelial or liver progenitor marker was coexpressed by genetically labeled HSCs in response to liver injury. Consistent with this, Chu et al. also found no cholangiocytes undergone EMT in murine models of hepatic fibrosis. Although they observed that cultured primary cholangiocytes can undergo EMT (i.e., loss of cell–cell contacts and acquisition of fibroblast-like morphology) after TGF-β1 treatment, but in the mouse BDL and CCL4 models, the investigators found that cholangiocytes do not undergo EMT in vivo. Moreover, they further demonstrated that EMT does not occur in cholangiocyte precursors (oval cells). However, further studies are still needed to confirm whether cholangiocyte EMT contributes to liver fibrosis.

Hepatic stellate cell and MET

HSC is the best studied fibrogenic mesenchymal cell in the liver. Now HSCs, as the main source of ECM, have been corroborated to be the dominant contributors to liver fibrosis independent of its etiology. The concept that HSCs are able to undergo MET is intriguing. Sicklick et al. analyzed the expression profile of HSC, HSC cell lines, and hepatic epithelial progenitors and found that epithelial progenitors express HSC markers. Furthermore, epithelial progenitor microRNAs were also expressed by HSC cell lines. In addition, HSCs that express progenitor cell markers were confirmed with the potential to differentiate into hepatocytes when cultured under certain condition. Yovchev et al. revealed that oval cells coexpressed epithelial and mesenchymal markers, and transplantation of these hepatic progenitor cells could repopulate injured livers. Choi et al. even found that transition of quiescent HSCs between epithelial and mesenchymal fates were regulated by Hh signaling pathway. Loss of E-cadherin is a characteristic behavior of EMT. Cho et al. reported that E-cadherin is capable of inhibiting TGF-β1 gene induction in HSCs by suppressing RhoA-dependent Smad3 phosphorylation and preventing liver fibrosis. But Scholten et al. using cell fate tracing technique, found no epithelial markers coexpressed by HSCs in response to fibrogenic liver injury in mice. However, Conigliaro et al. reported that hepatocytes and HSCs may arise from common progenitor isolated from embryonic livers. Their study also showed that these progenitor cells were able to transdifferentiate into both hepatocytes and HSCs in vitro and in vivo. Interestingly, Yang et al. found that HSCs can secrete type I collagen to trigger EMT of hepatoma cells. Zhao et al. found that microRNA-21 (miR-21) can simultaneously promote HSC activation and hepatocyte EMT in liver fibrosis. They also confirmed that miR-155 can modulate similar process. Collectively, there seems to be plenty of evidence indicating that HSCs can undergo MET during hepatic fibrogenesis. But more recently, Lua et al. demonstrated that HSCs are not capable of differentiating into either hepatocytes or cholangiocytes in mouse. Using cell lineage tracing technique, they found that mesodermal mesenchymal cells, including HSCs and portal fibroblasts, comprise a major source of MFs and do not undergo MET during fibrogenesis. In addition, they even found that no HSCs contributed to oval cells via MET. This was supported by research from Troeger et al. Troeger et al. employed single-cell polymerase chain reaction and genetic cell fate tracking to investigate whether HSC deactivation represents an alternative mechanism for liver fibrosis resolution. They found that HSC activation gradually decreased during fibrosis reversal and no HSC contributed to hepatocytes and cholangiocytes via MET. Together, these data provided fairly good evidence that refutes the notion that HSCs undergo MET to yield either hepatocytes or cholangiocytes. The contradictory conclusion from Yang and colleagues’ report may result from the inappropriate engagement of HSC marker.

MAIN SIGNALING PATHWAYS IMPLICATED IN EMT

Hedgehog Signaling Pathway and EMT

Signaling pathways involved in EMT have been explored substantially, and one of the well-documented pathways is Hh signaling. The Hh pathway plays crucial role in organogenesis and tissue remodeling. Recent studies suggest that activation of Hh pathway appears to be implicated in fibrogenesis through regulation of EMT. Omenetti et al. showed that in rodent model induced by BDL, Hh signaling was activated to guide remodeling of the biliary epithelia and stroma after cholestatic injury. They further revealed that enhanced EMT responses to BDL were related to excessive
activation of Hh pathway, which promotes biliary fibrosis progression.\(^{[73]}\) Syn et al.\(^{[59]}\) found that in nonalcoholic fatty liver disease (NAFLD), sonic Hh suppressed expression of epithelial genes and EMT inhibitors but induced mesenchymal genes in cultured progenitors of ductular cell. In mouse models of NAFLD, they also found that activation of Hh pathway was followed by EMT, expansion of myofibroblastic populations, and liver fibrosis.\(^{[59]}\) In addition, researchers found that Hh pathway functions critically in transition of quiescent HSCs into myofibroblastic HSCs, and enables quiescent HSC to transit between epithelial and mesenchymal fates.\(^{[48]}\) Omenetti et al.\(^{[54]}\) demonstrated that Hh signaling was excessively activated in biliary atresia and resulted in biliary EMT, which may lead to biliary dysmorphogenesis and finally fibrosis. Interestingly, Yu et al.\(^{[62]}\) recently reported that patched1, a negative regulator of Hh pathway, was downregulated during liver fibrosis. They further confirmed that decreased expression of patched1 was associated with its DNA hypermethylation. Sltianolic acid B can induce miR-152 to target DNA methyltransferase 1 and demethylate patched1; thus prevent liver fibrosis by inhibiting Hh signaling-induced EMT.\(^{[62]}\) Although these data provide evidence that Hh signaling pathway can regulate EMT, given the questioned existence of EMT of hepatocytes or cholangiocytes, its contribution to liver fibrosis remains a subject of some debate. However, it is indisputable that Hh signaling can coordinate epithelial–mesenchymal interactions to regulate repair and regeneration and maintain tissue homeostasis.\(^{[63]}\)

**TGF-β Signaling Pathway and EMT**

TGF-β has been commonly recognized as a critical factor stimulating collagen and ECM production in HSCs during hepatic fibrogenesis.\(^{[64]}\) Kaimori et al.\(^{[25]}\) reported that TGF-β1 is capable of mediating EMT in hepatocytes in vitro. They found that administration of TGF-β1 significantly increased α1 collagen mRNA expression and type I collagen deposition, which were defined as the characteristic of EMT state.\(^{[25]}\) They also showed that in the EMT state, TGF-β1 induced snail-1 and activated Smad2/3 pathway in hepatocytes, while silencing Smad4 inhibited EMT.\(^{[25]}\) Similarly, Kojima et al.\(^{[26]}\) reported that in mature hepatocytes, EMTs were induced by TGF-β-mediated downregulation of claudin-1. Furthermore, studies revealed that hepatocytes actively participated in fibrogenesis after EMT induced by TGF-β, whereas specific ablation of TGF-β signaling by Smad7 in hepatocytes effectively slack the fibrogenic response.\(^{[17]}\) Rygiel et al.\(^{[36]}\) also showed that EMT in response to TGF-β contributes to portal tract fibrogenesis. Recently, Kong et al.\(^{[28]}\) confirmed that curcumin can inhibit EMT in hepatocytes by interfering with TGF-β/Smad signaling. Schizandrin and propolis have also been shown to inhibit fibrosis and EMT induced by TGF-β.\(^{[65,66]}\) Transmembrane 4 L6 family member 5 (TM4SF5) is a transmembrane glycoprotein which can induce EMT and is highly expressed in hepatocellular carcinoma.\(^{[67]}\) Investigators found that expression of TM4SF5 in hepatocytes can be induced by TGF-β1 and epidermal growth factor receptor (EGFR) signaling pathways.\(^{[67]}\) Increased TM4SF5 expression was found in CCl4-mediated liver fibrosis mouse model and correlated with α-SMA expression, collagen I deposition, and TGF-β1 and EGFR signaling activation.\(^{[68]}\) Interestingly, as a kinase inhibitor drug approved for the treatment of cancer, sorafenib was confirmed to be capable of inhibiting TGF-β-mediated EMT in hepatocytes and fibrosis.\(^{[67,69]}\) Collectively, TGF-β and its related proteins are major inducers of EMT. However, contrary to the popular notion that TGF-β is a main contributor to liver fibrosis,\(^{[70]}\) Mu et al.\(^{[71]}\) showed that epithelial TGF-β signaling does not promote liver fibrosis, but inhibits cholangiocytes proliferation to prevent cholangiocarcinoma development.\(^{[71]}\) Therefore, further studies are needed to clarify whether TGF-β-induced EMT plays a role in liver fibrosis.

**Extracellular Signal-Regulated Kinase Signaling Pathway and EMT**

Extracellular signal-regulated kinases (ERKs), namely the classical mitogen-activated protein (MAP) kinases, are serine/threonine kinases that play crucial roles in the modulation of cell growth and differentiation.\(^{[73]}\) Evidence suggests that ERK signaling contributes to repression of EMT.\(^{[73,74]}\) Arnoux et al.\(^{[77]}\) reported that Erk5 controls the expression of slug, which involves the basal keratinocyte activation, spreading, and migration and contributes to re-epithelialization during cutaneous wound healing. Thum et al.\(^{[75]}\) showed that increased ERK–MAP kinase activity promotes interstitial fibrosis and cardiac function and this process can be inhibited by miR-21. In liver fibrosis, Zhong et al.\(^{[76]}\) found that reduced ERK1 expression suppressed HSCs proliferation and their expression of fibrosis-related genes in vitro; specific inhibition of ERK1 significantly weakens ECM deposition in fibrotic liver. They also found that myofibroblasts derived from hepatocytes and cholangiocytes were reduced markedly by selective inhibition of ERK1.\(^{[76]}\) Dai et al.\(^{[83]}\) reported that miRNA-21 was significantly higher in cirrhotic patients and rats, and sprouty 2 (SPRY2) and hepatocyte nuclear factor 4α (HNF4α) were identified as effective targets of miR-21. By targeting SPRY2 and HNF4α, miR-21 simultaneously stimulates ERK1 signaling in HSCs and induces hepatocytes EMT.\(^{[83]}\) In another report, they found that miR-155, on the contrary, simultaneously suppresses EMT process and
ERK1 signaling, attenuates HSC activation, and prevents hepatic fibrosis.\textsuperscript{[54]} These studies showed that inhibition of ERK signaling contributes to prevention of liver fibrosis, and EMT may be involved in this process.

**Future perspectives**

As a solid organ, the liver has a striking ability to adapt to damage through tissue repair, but excessive accumulation of ECM proteins during this wound healing response will lead to liver fibrosis; this highlights the significance of the balance of this process. Nevertheless, the complicated mechanisms underlying hepatic fibrogenesis have not been fully elucidated. The past decades have witnessed enormous progress in our understanding of hepatic fibrosis, and the discovery of EMT/MET provides us with new insights into its pathogenesis. However, in the light of conflicting evidence that refutes the role of EMT/MET in liver fibrosis, perhaps our enthusiasm should be curbed. Yet despite this, the role of EMT in hepatocellular carcinoma (HCC) has been identified recently. Although EMT has been proved not indispensable for breast cancer and pancreatic cancer metastasis,\textsuperscript{[77,78]} its contribution to HCC metastasis and invasion has been confirmed and thus may serve as a prognosis predictor.\textsuperscript{[79‑82]} In addition, studies have revealed that EMT could induce chemoresistance in some types of cancer.\textsuperscript{[77,78]} Therefore, a comprehensive understanding of EMT is urgently needed and will enable the development of novel diagnostic and effective therapeutic strategies to prevent HCC progression and improve patients’ prognosis.

**Acknowledgement**

This work was funded by the Natural Science Foundation of China (Nos 81101240 and 81371821).

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Kalluri R, Neilson EG. Epithelial–mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776‑84.
2. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell 2009;139:871‑90.
3. Hay ED. Organization and fine structure of epithelium and mesenchyme in the developing chick embryo. Epithelial Mesenchymal Interactions 1968;2:31‑5.
4. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131‑42.
5. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442‑54.
6. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis.

Yu, et al.: EMT in liver fibrosis

Science 2011;331:1559‑64.
7. Arnoux V, Nassour M, L’Helgoualc’h A, Hipskind RA, Savagner P. Erk5 controls slug expression and keratinocyte activation during wound healing. Mol Biol Cell 2008;19:4738‑49.
8. Carey RM, Wang B, Kantharidis P. The role of EMT in renal fibrosis. Cell Tissue Res 2012;347:103‑16.
9. Kriz W, Kaisling B, Le Hir M. Epithelial‑mesenchymal transition (EMT) in kidney fibrosis: Fact or fantasy? J Clin Invest 2011;121:468‑74.
10. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209‑18.
11. Lotersztajn S, Julien B, Teixeira‑Clerc F, Grenard P, Mallat A. Hepatic fibrosis: Molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005;45:605‑28.
12. Rockey DC, Bell PD, Hill JA. Fibrosis — A common pathway to organ injury and failure. N Engl J Med 2015;372:1138‑49.
13. Pellicoro A, Ramachandran P, Iredale JP, Fallowsfield JA. Liver fibrosis and repair: Immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014;14:181‑94.
14. Yin C, Evasion KJ, Ashina K, Stainier DY. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest 2013;123:1902‑10.
15. Wang FS, Zhang Z. Liver: How can acute‑on‑chronic liver failure be accurately identified? Nat Rev Gastroenterol Hepatol 2013;10:390‑1.
16. Nitta T, Kim JS, Mohouby Z, Behrens KE. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 2008;48:909‑19.
17. Dooley S, Harzavi J, Guedan L, Godoy P, Ilkovets I, Ehnert S, et al. Hepatocyte‑specific Smad7 expression attenuates TGF‑beta‑mediated fibrogenesis and protects against liver damage. Gastroenterology 2008;135:642‑59.
18. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007;46:48‑57.
19. Wells RG. The epithelial‑to‑mesenchymal transition in liver fibrosis: Here today, gone tomorrow? Hepatology 2010;51:737‑40.
20. Popov Y, Schuppan D. Epithelial‑to‑mesenchymal transition in liver fibrosis: Dead or alive? Gastroenterology 2010;139:722‑5.
21. Kalluri R. EMT: When epithelial cells decide to become mesenchymal‑like cells. J Clin Invest 2009;119:1417‑9.
22. Kalluri R, Weinberg RA. The basics of epithelial‑mesenchymal transition. J Clin Invest 2009;119:1420‑8.
23. Zeisberg M, Yang C, Martinito M, Duncan MB, Rieder F, Tanjore H, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to fibroblastic transition. J Biol Chem 2007;282:23337‑47.
24. Choi SS, Diehl AM. Epithelial‑to‑mesenchymal transitions in the liver. Hepatology 2009;50:2007‑13.
25. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Kotesh A. Transforming growth factor‑beta1 induces an epithelial‑to‑mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 2007;282:22089‑101.
26. Kojima T, Takano K, Yamamoto T, Murata M, Son S, Imamura M, et al. Transforming growth factor‑beta induces epithelial‑to‑mesenchymal transition by down‑regulation of Claudin‑1 expression and the fence function in adult rat hepatocytes. Liver Int 2008;28:534‑45.
27. Lee WR, Kim KH, An HJ, Kim YJ, Lee SJ, Han SM, et al. Apanin inhibits hepatic fibrosis through suppression of transforming growth factor beta1‑induced hepatocyte epithelial‑mesenchymal transition. Biochem Biophys Res Commun 2014;450:195‑201.
28. Dong K, Zhang F, Shao J, Wu L, Zhang X, Chen L, et al. Carcemin inhibits cobalt chloride‑induced epithelial‑to‑mesenchymal transition associated with interference with TGF‑beta/Smad signaling in hepatocytes. Lab Invest 2015;95:1234‑45.
29. Park JH, Yoon J, Lee KY, Park B. Effects of geniposide on hepatocytes undergoing epithelial‑mesenchymal transition in hepatic fibrosis by targeting TGFbeta/Smad and ERK‑MAPK signaling pathways. Biochimie 2015;113:236‑34.
30. Wen SL, Gao JH, Yang WJ, Lu YY, Tong H, Huang ZY, et al.
Yu, et al.: EMT in liver fibrosis

Clececoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes. J Gastroenterol Hepatol 2014;29:1932-42.

31. Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, Penz-Osterreicher M, et al. Hepatocytes do not undergo epithelial–mesenchymal transition in liver fibrosis in mice. Hepatology 2010;51:1027-36.

32. Lemaigre FP. Determining the fate of hepatic cells by lineage tracing: Facts and pitfalls. Hepatology 2015;61:2100-3.

33. Omenetti A, Porrello A, Jung Y, Yang L, Omenetti A, Popov Y, Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, et al. Evidence for epithelial–mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in advanced liver fibrosis. Verh Dtsch Ges Pathol 2007;91:250-6.

34. Deng YH, Pu CI, Li YC, Zhu J, Zhang MM, et al. Analysis of biliary epithelial–mesenchymal transition in biliary atresia. Dig Dis Sci 2011;56:731-40.

35. Xiao Y, Zhou Y, Chen Y, Zhou K, Wen J, Wang Y, et al. The expression of epithelial–mesenchymal-transition-related proteins in biliary epithelial cells is associated with liver fibrosis in biliary atresia. Pediatr Res 2015;77:310-5.

36. Schulze F, Schardt K, Wedemeyer I, Konze E, Wendland K, Dirsch O, et al. Epithelial–mesenchymal transition of biliary epithelial cells in liver fibrosis. Dtsch Med Wochenschr 2010;135:1107-12.

37. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, et al. Genetic labeling does not detect epithelial–mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 2010;139:1478-88.e8.

38. Yu F, Lu Z, Chen B, Wu X, Dong P, Zheng J, et al. Hedgehog-mediated epithelial–mesenchymal interactions modulate hepatic response to bile duct ligation. Lab Invest 2007;87:499-514.

39. Rygiel KA, Robertson H, Marshall H, Pekalski M, Zhao L, Booth TA, et al. Determining the fate of hepatic cells by lineage tracing: Facts and pitfalls. Hepatology 2015;61:2100-3.

40. Schulze F, Schardt K, Wedemeyer I, Konze E, Wendland K, Dirsch O, et al. Epithelial–mesenchymal transition of biliary epithelial cells in advanced liver fibrosis. Verh Dtsch Ges Pathol 2007;91:250-6.

41. Deng YH, Pu CI, Li YC, Zhu J, Zhang MM, et al. Analysis of biliary epithelial–mesenchymal transition in biliary atresia. Dig Dis Sci 2011;56:731-40.

42. Schulze F, Schardt K, Wedemeyer I, Konze E, Wendland K, Dirsch O, et al. Epithelial–mesenchymal transition of biliary epithelial cells in liver fibrosis. Dtsch Med Wochenschr 2010;135:1107-12.

43. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, et al. Evidence for epithelial–mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in advanced liver fibrosis. Verh Dtsch Ges Pathol 2007;91:250-6.

44. Deng YH, Pu CI, Li YC, Zhu J, Zhang MM, et al. Analysis of biliary epithelial–mesenchymal transition in biliary atresia. Dig Dis Sci 2011;56:731-40.

45. Xiao Y, Zhou Y, Chen Y, Zhou K, Wen J, Wang Y, et al. The expression of epithelial–mesenchymal-transition-related proteins in biliary epithelial cells is associated with liver fibrosis in biliary atresia. Pediatr Res 2015;77:310-5.

46. Diaz R, Kim JW, Hui JJ, Li Z, Swain GP, et al. Evidence for the epithelial to mesenchymal transition in biliary atresia fibrosis. Hum Pathol 2008;39:102-15.

47. Schulten D, Osterreicher CH, Scholtan A, Iwaisako K, Gu G, Brenner DA, et al. Genetic labeling does not detect epithelial–mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 2010;139:987-98.

48. Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, et al. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 2011;53:1685-95.

49. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013;19:1617-24.

50. Troeger JS, Mederacke I, Gwak GY, Dapito DH, Xu M, Hsu CC, et al. Hedgehog-mediated epithelial–mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 2010;52:2053-64.

51. Coniglio A, Amicone L, Costa V, De Santis Puzzonia M, Mancone C, Sacchetti B, et al. Evidence for a common progenitor of epithelial and mesenchymal components of the liver. Cell Death Differ 2013;20:1116-23.

52. Yang MC, Wang CJ, Liao PC, Yen CJ, Shan YS. Hepatic stellate cells secretes type I collagen to trigger epithelial mesenchymal transition of hepatoma cells. Am J Cancer Res 2014;4:751-63.

53. Zhao J, Tang N, Wu K, Dai W, Ye C, Shi J, et al. MiR-21 simultaneously regulates ERK1 signaling in HSC activation and hepatocyte EMT in liver fibrosis. PLoS One 2014;9:e108005.

54. Dai W, Zhao J, Tang N, Zeng X, Wu K, Ye C, et al. MicroRNA-155 attenuates activation of hepatic stellate cell by simultaneously preventing EMT process and ERK1 signalling pathway. Liver Int 2015;35:1234-43.

55. Lua I, James D, Wang J, Wang KS, Asahina K. Mesodermal mesenchymal cells give rise to myofibroblasts, but not epithelial cells, in mouse liver injury. Hepatology 2014;60:311-22.

56. Troeger JS, Mederacke I, Gwak GY, Dapito DH, Xu M, Hsu CC, et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 2012;143:1073-83.e22.

57. Ingham PW, Mcmahon AP. Orchestrating ontogenesis: Variations on a theme by sonic hedgehog. Nat Rev Genet 2006;7:841-50.

58. Ingham PW, Placzek M. Hedgehog signaling in animal development: Paradigms and principles. Genes Dev 2001;15:3059-87.

59. Ingham PW, Mcmahon AP. Orchestrating ontogenesis: Variations on a theme by sonic hedgehog. Nat Rev Genet 2006;7:841-50.

60. Omenetti A, Popov Y, Jung Y, Choi SS, Witek RP, Yang L, et al. Hedgehog-mediated epithelial–mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009;137:1478-88.e8.

61. Omenetti A, Porrello A, Jung Y, Yang L, Omenetti A, Popov Y, Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, et al. Evidence for epithelial–mesenchymal transitions in adult liver. Hepatology 2010;51:1027-36.

62. Omenetti A, Porrello A, Jung Y, Yang L, Omenetti A, Popov Y, Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, et al. Evidence for epithelial–mesenchymal transitions in adult liver. Hepatology 2010;51:1027-36.

63. Ingham PW, Mcmahon AP. Orchestrating ontogenesis: Variations on a theme by sonic hedgehog. Nat Rev Genet 2006;7:841-50.

64. Troeger JS, Mederacke I, Gwak GY, Dapito DH, Xu M, Hsu CC, et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 2012;143:1073-83.e22.

65. Ingham PW, Mcmahon AP. Orchestrating ontogenesis: Paradigms and principles. Genes Dev 2001;15:3059-87.

66. Ingham PW, Mcmahon AP. Orchestrating ontogenesis: Variations on a theme by sonic hedgehog. Nat Rev Genet 2006;7:841-50.
71. Mu X, Pradere JP, Affo S, Dapito DH, Friedman R, Lefkovitch JH, \textit{et al.} Epithelial transforming growth factor-beta signaling does not contribute to liver fibrosis but protects mice from cholangiocarcinoma. Gastroenterology 2016;150:720-33.

72. Rao VN, Reddy ES. Elk-1 proteins interact with MAP kinases. Oncogene 1994;9:1855-60.

73. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-96.

74. Ichikawa K, Kubota Y, Nakamura T, Weng JS, Tomida T, Saito H, \textit{et al.} MCRIP1, an ERK substrate, mediates ERK-induced gene silencing during epithelial-mesenchymal transition by regulating the co-repressor CtBP. Mol Cell 2015;58:35-46.

75. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, \textit{et al.} MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-4.

76. Zhong W, Shen WF, Ning BF, Hu PF, Lin Y, Yue HY, \textit{et al.} Inhibition of extracellular signal-regulated kinase 1 by adenovirus mediated small interfering RNA attenuates hepatic fibrosis in rats. Hepatology 2009;50:1524-36.

77. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, \textit{et al.} Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015;527:525-30.

78. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, \textit{et al.} Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015;527:472-6.

79. Wang YP, Yu GR, Lee MJ, Lee SY, Chu IS, Leem SH, \textit{et al.} Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Len2/Twist1 pathway. Hepatology 2013;58:1349-61.

80. Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF, \textit{et al.} Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res 2016;76:818-30.

81. Meng FD, Wei JC, Qu K, Wang ZX, Wu QF, Tai MH, \textit{et al.} FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma. World J Gastroenterol 2015;21:196-213.

82. Hou KZ, Fu ZQ, Gong H. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. World J Gastroenterol 2015;21:475-83.